Business Desk :
Novo Nordisk, a Danish pharmaceutical giant and one of the largest insulin maker, is going to launch a new type of insulin “Ryzodeg” for type 2 diabetic patients in Bangladesh, says a press release.
Ryzodeg® is a simple regimen with fewer injections than basal-bolus therapy that provides successful reduction of blood glucose with less chances of hypoglycaemia compared to conventional insulins, said A Rajan Kumar, managing director of Novo Nordisk Pharma (Pvt.) Ltd.
People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful. Ryzodeg requires only two injections daily, Rajan said.
Novo Nordisk, the global leader in diabetes care, has always been striving to develop products that address key challenges faced by people with diabetes and physicians, he said.
Ryzodeg® is a combination of two distinct insulin analogues, degludec and as part with ratio of 70:30.
Novo Nordisk, a Danish pharmaceutical giant and one of the largest insulin maker, is going to launch a new type of insulin “Ryzodeg” for type 2 diabetic patients in Bangladesh, says a press release.
Ryzodeg® is a simple regimen with fewer injections than basal-bolus therapy that provides successful reduction of blood glucose with less chances of hypoglycaemia compared to conventional insulins, said A Rajan Kumar, managing director of Novo Nordisk Pharma (Pvt.) Ltd.
People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful. Ryzodeg requires only two injections daily, Rajan said.
Novo Nordisk, the global leader in diabetes care, has always been striving to develop products that address key challenges faced by people with diabetes and physicians, he said.
Ryzodeg® is a combination of two distinct insulin analogues, degludec and as part with ratio of 70:30.
